Biomedical, Clinical & Life Sciences

Limit: 1 // Tickets Available: 0 

D. Axon (College of Pharmacy) - Competitive Resubmission
 

Limit: 2 // Available: 0
Y. Bai (Optical Sciences)
S. Kong (Astronomy) 
 

Eligibility: 

Must be a faculty members in the first three years of their faculty careers, that is, whose initial faculty appointments began no earlier than May 31, 2022, and no later than May 31, 2025.
 

The  Packard Fellowships for Science and Engineering Program invests in future leaders who have the freedom to take risks, explore new frontiers in their fields of study, and follow uncharted paths that may lead to groundbreaking discoveries.

Candidates must be faculty members who are eligible to serve as principal investigators engaged in research in the natural and physical sciences or engineering and must be within the first three years of their faculty careers. Disciplines that will be considered include physics, chemistry, mathematics, biology, astronomy, computer science, earth science, ocean science, and all branches of engineering. Candidates engaged in research in the social sciences will not be considered. 

The Fellowship Program provides support for highly creative researchers early in their careers; faculty members who are well-established and well-funded are less likely to receive the award.  Packard Fellows are inquisitive, passionate scientists and engineers who take a creative approach to their research, dare to think big, and follow new ideas wherever they lead.  

The Foundation emphasizes support for innovative individual research that involves the Fellows, their students, and junior colleagues, rather than extensions or components of large-scale, ongoing research programs.  
 

Limit: 3 // Available: 0
S. Goldman (Sarver Heart Center, COM-T)
E. Eggers (Physiology - COM-T)
J.H. Stern (Medicine - COM-T)

The submission of this funding program is coordinated by RSD with the assistance of the University of Arizona Foundation. For more information, please contact Selena Valencia-Salazar. 

The mission of The G. Harold and Leila Y. Mathers Foundation is to advance knowledge in the life sciences by sponsoring scientific research that will benefit mankind. The foundation’s grants program seeks to support basic science, ideally with potential translational applications. Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.

For many years the Foundation has enjoyed special recognition in the research community for supporting “basic” scientific research, realizing that true transformative breakthroughs usually occur after a thorough understanding of the fundamental mechanisms underlying natural phenomena. More recently, and with the advent of newer investigative methodologies, technology, and tools, the Foundation now embraces innovative translational research proposals.

The grant duration must be three years. The budget should be reasonable based on the aims of the project. Indirect costs may not exceed 10%. Preliminary Budgets are required during the LOI phase. A detailed budget justification is not required until the proposal phase. The Foundation’s grant award is not intended to be utilized for purchasing capital equipment (“bricks-and-mortar”) for the lab and is intended only to support the actual investigation. The Foundation assumes and expects that capital equipment must be provided by the research institution or university.

Application Guidance:

• Grant budgets cannot exceed $600-750K
• The Foundation primarily supports basic science, ideally with potential translational applications.
• Immunology, microbiome, genomics, structural biology, cellular physiology, neuroscience, etc., are some noteworthy examples of current research support.
• Covid-19-related research projects (aims or sub-aims) will not be considered for support.
• Medical imaging technology-related projects and/or electrical engineering technology development projects will not be considered for support.
• Plant Biology Research, Oceanography, Space Exploration. and Global warming-related research will not be considered for support.
• As technology continues to advance, it is apparent that investigations in the area of basic science and translational research may become more and more reliant on collaborative, interdisciplinary projects. It is important to note that any interdisciplinary project proposals may require additional information regarding the collaborator(s)’ achievements and relevant expertise.
• Feedback for declined LOI Requests will not be provided; LOIs or Formal Proposals that have been declined should not be resubmitted at a later date for consideration.
• Renewal applications for the same or related research will not be accorded priority consideration. It is strongly advised that any re-application for grant renewal consider a new direction based on prior research or emphasize some new potential translational aspects and not merely an extension of previously funded research.
• Requests for funding previously federally supported research and/or applications pending federal approval will not be accorded priority consideration.
• Requests for support of clinical trials or drug discovery will not be approved. The Foundation will not support projects which we consider pre-clinical drug development.Spring 2025 Cycle Deadlines: 

Nominations and Portal Registration due date: February 28, 2025 (Friday, 8 PM EST (5 PM PST)

Due date for LOI applications: March 14, 2025 (Friday, 8 PM EST (5 PM PST)
Applicants are notified of proposal invitation or LOI rejection within 30 days of the due date.

Due date for invited formal proposals: May 23, 2025 (Friday, 8 PM EST (5 PM PST)
Applicants are notified of proposal approval or rejection within 75 days of the due date.

No Applicants // Limit: 5 // Tickets Available: 5

The University of Arizona Cancer Center (UACC) can nominate five applications for the Damon Runyon Clinical Investigator Award. 

For more information please contact: UACC-PreAward.

Purpose of Award 

The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine.

The Clinical Investigator Award responds to three recognized realities:

• Though there has never been a more pressing need or more promising time for clinical cancer research, fewer young physicians enter this area of investigation every year.
• The number of institutions committed to training young physicians in the scientific discipline and methodologies of clinical investigation is critically low.
• The burden of medical school debt (averaging over $100,000) discourages many physicians from pursuing clinical investigation.

The Damon Runyon Cancer Research Foundation’s award offers solutions to these realities. The awardee will receive financial support for three years, as well as assistance with certain research costs such as the purchase of equipment. The Foundation will also retire up to $100,000 of any medical school debt still owed by the awardee.

The Clinical Investigator Award program is specifically intended to provide outstanding young physicians with the resources and training structure essential to becoming successful clinical investigators. The goal is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments.

Eligibility

• The applicant must hold an independent Assistant Professor position or equivalent at a U.S. institution and is expected to demonstrate significant support from the home institution through a comprehensive start-up package, ample laboratory space, and protected research time, for example.
• The applicant must have received an MD, DO, or MD/PhD degree(s) from an accredited institution, completed their subspecialty training and be U.S. Board eligible.
• The applicant must hold a valid, active U.S. medical license at the time of application.
• The applicant must apply within the first five (5) years of their Assistant Professor or equivalent full faculty appointment (Cut-off date: July 1, 2020). Instructor, Adjunct and/or acting positions are not eligible.
• Candidates holding or awarded R01s (or R01-equivalent grants such as the DP2 and DP5) at the time of application are not eligible to apply.
• The applicant must commit to spending 80% of their time conducting research. [In rare unique circumstances, the CIA Committee may consider an applicant with a very modest reduction of 80% protected time if their Department Chair can provide a compelling reason explaining why a waiver of the 80% requirement should be granted, what percentage of effort will be guaranteed, and what safeguards will be put in place to make sure the individual’s research will not be compromised by their clinical/administrative activities.]
• The applicant is required to apply in conjunction with a Mentor who is established in the field of clinical translational cancer research, cancer prevention and/or epidemiology and can provide the critical guidance needed during the period of the award. No more than two Damon Runyon Clinical Investigators will be funded to work with the same Mentor at any given time (including Co-Mentors).
• Candidates may apply up to two times during this eligibility period.
• Only one application will be accepted from a Mentor per review session (including Co-Mentors).

Limit: 3* // Tickets Available: 2

* Limit one ticket per category: 
 - Research Grant: Limit: 1 // Available: 0 
K. Huntoon (Neurosurgery)
- Scholar (CDA): Limit: 1 // Available: 1
- International Scholar Limit: 1 // Available: 1

The St. Baldrick’s Foundation works hard to be sure that every dollar makes the biggest impact possible in childhood cancer research. The Foundation is proud to have received the National Cancer Institute Peer Review Funder designation for selection of grants. The Foundation has held several Research Priorities Summits with many of the country’s leading pediatric oncology researchers participating to advise the staff and board of directors on funding priorities.
The St. Baldrick’s team and scientific advisors meet regularly to be sure St. Baldrick’s
funds make the greatest impact on pediatric cancer research.

Current funding priorities are divided into four categories:

• New discovery research
• Translational research and early phase clinical trials
• Phase III clinical trials & infrastructure support of participating institutions
  (primarily the fall grant cycle)
• Education of new pediatric oncology researchers
   

In addition to research to understand the biology of childhood cancers and discover
leads to more effective treatments, topics of interest include, but are not limited to:

• Adolescents & young adults
• Survivorship, outcomes, and quality of life
• Supportive care
• Epidemiology and pediatric cancer predispositions
•  Precision medicine
• Alternative & complementary therapies

Limit: 1 // Tickets Available: 0 

J. Andrews (College of Medicine - Tucson) 

Only one application per institution (normally identified by having a unique UEI number) is allowed. Applicants can apply for Component A or Component B; however, applicants cannot apply for both Component A and Component B.

Purpose: 
The objective of this NOFO is to conduct surveillance of diabetes in youth (< 18 years) and young adults (18–44 years) across health system and/or health plan membership-based centers to provide estimates of diabetes incidence and prevalence in the United States. These estimates are sought by diabetes type, demographic traits, health insurance status, and geographic area to identify disparities in diabetes burden. The prevalence of diabetes complication risk factors, acute and chronic diabetes complications, and use of diabetes medications among youth and young adults with diabetes will also be ascertained.

This project has two (2) components to achieve the purpose of the program. Component A focuses on surveillance of diabetes among youth (< 18 years) and young adults (18–44 years). Component B serves as a Coordinating Center to provide an infrastructure for standardized approaches, analytical methods, and measures to be used for surveillance across sites. It will also develop validation protocols, serve as a data repository, and provide statistical expertise.

Limit: 1 // Available: 0

M. Herbst-Kralovetz (Cancer Center)


The Mary Kay Ash Foundation®, a funding source for cancer research, is currently accepting applications for innovative grants for translational research of cancers affecting women, including but not limited to breast, cervical, endometrial, ovarian, uterine or cancers predominantly affecting women. 

Award Amount

The grant period is two years beginning September 1, 2025 – September 1, 2027*. Contracts are distributed to the final awardees in early June. 

Eligibility 

• The Principal Investigator must be a full-time assistant professor or higher at the time of application submission and commit a minimum 5% effort. Pending future appointments will not be honored.
• U.S. citizenship is not required.
• One Co-PI is permitted and must meet the same eligibility requirements as the PI. International Co-PIs are permitted with the caveat that all funds will be designated to the U.S.-based university. Post-doc contributors must be listed as co-investigators, not PIs.

Budget

• The total budget over two years may not exceed $100,000 (combined indirect/direct costs).
• The budget should follow the NIH format for a two-year grant ($50,000/year) and include justification.
• The NIH salary cap of $199.300 must be followed
• Indirect costs must not exceed 15% of direct costs .

Allowable Activities and Expenses

• Animal studies are allowed. However, researchers will need to indicate how their studies would impact patient care in the future should their research be successful.

• Equipment and travel costs must be justified

   

Application Requirements

A complete application must include the following:

• Research Description (6 pages max)
• Literature References Cited (2 pages max)
• Letters of Collaboration/Letters of Support (3 pages max)
• Current Financial Support (2 pages max)
• NIH-format Budget & Justification
• NIH-format Bio sketch or equivalent (5 pages max)
• If a co-PI or additional collaborators are included in your research team, please provide a brief resume for each.
• Preliminary data is not required, however it is helpful to include if available

Limit: 1 // Available: 0 

S. Soto (Public Health, Policy & Translational Research)

Maricopa County is committed to tackling the challenges of substance use in our community. The opioid settlement funds provide only a small part of what’s needed to address substance misuse in Maricopa County. The challenges are complex and the intent of MCDPH is to ensure that every dollar is used wisely to create the most impact. This means:

• Focus on projects that deliver immediate, measurable results and lay the groundwork for long-term change. The intent is to engage programs that meet urgent needs and address root causes of substance misuse so that the community benefits now and in the future. 

• Use strong data collection and evaluation practices to measure how well the programs work. This helps MCDPH to make informed decisions, improve our strategies, and ensure that funded programs truly make a difference. 

• Align our funding with other community resources. MCDPH will focus on areas where our money can fill gaps and support ongoing efforts, making our response as effective as possible. 

Organizations may choose to apply for one or more focus areas and may propose multiple activities under each focus area. However, each organization can only submit one application, and the total budget for all proposed activities may not exceed $500,000.